Avalo Therapeutics, Inc. financial data

Symbol
AVTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
540 Gaither Road, Suite 400, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Former names
Cerecor Inc. (to 8/18/2021)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 79.9 % +5.66%
Quick Ratio 0.07 % -49%
Debt-to-equity -434 % +69%
Return On Equity 32.6 % -97.7%
Return On Assets -9.06 % +91.6%
Operating Margin -7.68K % -505%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.4M shares -94.6%
Common Stock, Shares, Outstanding 9.68M shares -95%
Entity Public Float 4.8M USD -85.2%
Common Stock, Value, Issued 10K USD -94.8%
Weighted Average Number of Shares Outstanding, Basic 5.55M shares +2746%
Weighted Average Number of Shares Outstanding, Diluted 10.8M shares +5435%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 819K USD -63.6%
Selling and Marketing Expense 6.29M USD +180%
General and Administrative Expense 4.29M USD +72.1%
Costs and Expenses 63.7M USD +107%
Operating Income (Loss) -62.9M USD -120%
Nonoperating Income (Expense) 54.9M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.97M USD +76%
Income Tax Expense (Benefit) -9K USD -128%
Net Income (Loss) Attributable to Parent -7.96M USD +76%
Earnings Per Share, Basic 122 USD/shares
Earnings Per Share, Diluted 99.7 USD/shares +89.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 81.9M USD +704%
Accounts Receivable, after Allowance for Credit Loss, Current 38K USD
Inventory, Net 0 USD -100%
Assets, Current 86.1M USD +581%
Operating Lease, Right-of-Use Asset 1.14M USD -18.2%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Goodwill 10.5M USD -27.1%
Assets 98.5M USD +236%
Accounts Payable, Current 1.81M USD +130%
Employee-related Liabilities, Current 2.19M USD +388%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 60.7M USD +910%
Deferred Income Tax Liabilities, Net 154K USD -6.1%
Operating Lease, Liability, Noncurrent 1.08M USD -25.6%
Other Liabilities, Noncurrent 1.08M USD -25.6%
Liabilities 75.7M USD +420%
Retained Earnings (Accumulated Deficit) -335M USD -2.43%
Stockholders' Equity Attributable to Parent 21.1M USD +43.4%
Liabilities and Equity 98.5M USD +236%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.2M USD +38.3%
Net Cash Provided by (Used in) Financing Activities 109M USD +690%
Net Cash Provided by (Used in) Investing Activities 356K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 9.68M shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 103M USD +2784%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 82M USD +695%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 56.9M USD +8.71%
Deferred Tax Assets, Gross 56.8M USD +8.71%
Operating Lease, Liability 1.63M USD -18%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -121M USD -1118%
Lessee, Operating Lease, Liability, to be Paid 1.94M USD -21.2%
Operating Lease, Liability, Current 550K USD +2.61%
Lessee, Operating Lease, Liability, to be Paid, Year Two 563K USD +2.93%
Lessee, Operating Lease, Liability, to be Paid, Year One 553K USD +2.98%
Deferred Income Tax Expense (Benefit) 7K USD -12.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 303K USD -34.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 259K USD -53.5%
Deferred Tax Assets, Operating Loss Carryforwards 37.3M USD +15.1%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 201K USD -22.1%
Additional Paid in Capital 356M USD +4.25%
Amortization of Intangible Assets 0 USD -100%
Depreciation, Depletion and Amortization 34K USD +3.03%
Share-based Payment Arrangement, Expense 3.72M USD +5.05%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%